Handl Therapeutics

Leuven, Belgium Founded: 2019 • Age: 7 yrs Acquired By UCB
Developer of gene therapy to treat neurodegenerative diseases
Annual revenue - Latest available
Total funding - 1 rounds
Employees - Tracked headcount
Investors 2 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Handl Therapeutics

Handl Therapeutics is a company based in Leuven (Belgium) founded in 2019 by Michael Linden was acquired by UCB in November 2020. Handl Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Biogen and Alnylam, among others.

  • Headquarter Leuven, Belgium
  • Founders Michael Linden
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    $3.56 M (USD), Grant

    Sep 15, 2020

  • Investors
    UCB

    & 1 more

  • Employee Count
    Not available
  • Acquired by
    UCB

    (Nov 12, 2020)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Handl Therapeutics

Investors in Handl Therapeutics

Handl Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include UCB and VLAIO.

All
Institutional
Investor Description Founded Year Domain Location
Management consulting services are provided to businesses in Belgium.
Locked Locked Locked
Therapies for immunological and neurological disorders are developed.
Locked Locked Locked
Premium access

Investor details for Handl Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Handl Therapeutics

Investments
Premium access

Investment portfolio details for Handl Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Handl Therapeutics

Premium access

Detailed financials for Handl Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Handl Therapeutics Comparisons

Handl Therapeutics Primary company
Description
Developer of gene therapy to treat neurodegenerative disease...
Location
Leuven, Belgium
Founded Year
2019
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Handl Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Handl Therapeutics

Handl Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Biogen and Alnylam, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Therapeutics for genetic diseases are developed through targeted interventions.
Locked Locked Locked
Gene therapies for rare diseases including retinal dystrophies are developed.
Locked Locked Locked
Therapies for neurodegenerative and immunology disorders are developed.
Locked Locked Locked
RNA interference-based therapeutics are developed for multiple disorders.
Locked Locked Locked
A biopharmaceutical company accelerating innovative mental health treatments.
Premium access

Detailed competitors of Handl Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Handl Therapeutics

Premium access

Complete news archive for Handl Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Handl Therapeutics

Handl Therapeutics was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Handl Therapeutics is headquartered in Leuven, Belgium. It is registered at Leuven, Flemish Brabant, Belgium.

Handl Therapeutics was founded in 2019 and is headquartered in Leuven, Belgium. Focus is placed on the development of in vivo gene therapies targeting central nervous system diseases. Proprietary adeno-associated virus capsid technology is utilized to address neurodegenerative conditions. Operations center on advancing therapeutic solutions within the biotechnology sector, with emphasis on clinical and preclinical research for CNS applications.

Handl Therapeutics's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.

Handl Therapeutics has 2 investors. Key investors include UCB, and VLAIO.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available